- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Patient Navigation in Oncology at Heart of Priority Health White House Visit
On March 27, Priority Health's president and CEO, Praveen Thadani participated in a discussion on how to expand and optimize patient navigation services in oncology care, as part of the Cancer Moonshot initiative.
First Lady Dr Jill Biden | Image Credit: The White House
Praveen Thadani | Image Credit: Priority Health
Grand Rapids, Michigan — President and CEO of Priority Health Praveen Thadani traveled to the White House in late March to participate in a Cancer Moonshot discussion on how to improve and optimize patient navigation services in the oncology space, alongside First Lady Dr Jill Biden.
The first lady and Thadani, who recently lost his father to cancer, both emphasized the vital role a patient navigator fills for patients on this difficult, often uncertain, journey, noting that navigators help guide patients and their families and caregivers through the complex maze of the cancer care system.
“I saw firsthand through my father’s experience how complicated the journey can be,” said Thadani. “When you suffer from cancer, you go through a range of emotions, including fear, loss, anxiety and feeling overwhelmed. Navigators are a positive first step to offer much-needed support for cancer patients, caregivers and families during such a complex journey.”
The second largest health plan in Michigan, Priority Health servies more than 1.3 million members, offering both Medicare and Medicaid plan options.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
